Ocular inflammation drug to head to phase 3 clinical trial
cataract

Ocular inflammation drug to head to phase 3 clinical trial

Harrow, the manufacturer of TRIESENCE, hopes to expand the on-label usage of TRIESENCE for all cataract surgery patients.